Follow this innovation
[ via 
] [?]
Urine Biomarkers for Bladder Cancer
Children's Hospital Boston
posted on 11/27/2009
Bladder cancer is the second most common genitourinary cancer in the US. Using proteomics and antibody-based approaches, Dr. Zetter and colleagues found elevated levels of Cystatin B, a cathepsin protease inhibitor, in tissue and urine of bladder cancer patients compared to controls, and demonstrated a positive correlation between levels of Cystatin B and tumor grade, stage and shorter time to disease recurrence and progression.
File Number: CMCC 1337
Other Information:
*Investigator(s)*
Bruce Zetter
*Contact*
Maude Tessier, Maude.Tessier@childrens.harvard.edu
This innovation currently is not available for online licensing. Please contact David Altman at Children's Hospital Boston for more information.
request more info
ProfileFind more innovations
